In-vitro whole blood pharmacodynamics in rheumatoid arthritis

In-vitro whole blood pharmacodynamics in rheumatoid arthritis - In-vitro pharmacodynamics in rheumatoid arthritis

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON38292

Enrollment

200

Registered

2011-04-27

Start date

2011-11-18

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

arthritis chronic joint inflammation

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Patients with rheumatoid arthritis that have active disease and are selected to start with biological therapy (i.e. anti-TNF (etanercept, infliximab and adalimumab), rituximab, tocilizumab, abatacept or anakinra)

Exclusion criteria

Exclusion criteria: Patients that have no active disease

Design outcomes

Primary

Measure	Time frame
The most important outcome will be the interindividual differences in gene expression levels based on the ratio between untreated (t=0) and 24h/48h after in vitro addition of the specific drug to the whole blood.	—

Countries

Netherlands

Outcome results